BIONYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO.B
BIO-RAD LABORATORIES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$352.82−0.88 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $9.46B
- P/E (TTM)
- 42.8
- Dividend yield
- –
BIO-RAD LABORATORIES, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | $1.56B | $1.54B | $1.49B | $1.45B | $1.52B | $1.31B | $1.41B | $1.41B | $1.36B | $1.32B | 60.5% | +1.6% |
| Life Science | $1.02B | $1.03B | $1.18B | $1.35B | $1.40B | $1.23B | $885.90M | $861.70M | $785.20M | $730.70M | 39.5% | -0.7% |
| All Other Segments [Member] | $0 | $500.00K | $3.50M | $4.00M | $5.80M | $8.60M | $13.80M | $15.90M | $14.20M | $14.20M | 0.0% | -100.0% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | – | – | $229.60M | $217.70M | $181.80M | $138.30M | $148.50M | -$145.70M | $114.80M | $58.00M | – |
| Life Science | – | – | $108.90M | $266.80M | $319.70M | $282.60M | $72.10M | $28.70M | -$9.90M | -$19.10M | – |
| All Other Segments [Member] | – | – | -$700.00K | -$1.90M | -$1.20M | $400.00K | -$1.50M | $200.00K | $1.40M | $900.00K | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.02B | $1.04B | $1.12B | $1.16B | $1.13B | $1.00B | $899.10M | $863.60M | $800.20M | $770.60M | 39.6% | -1.8% |
| Europe [Member] | $881.80M | $834.10M | $819.80M | $851.90M | $946.90M | $857.70M | $770.30M | $792.00M | $758.50M | $742.20M | 34.1% | +5.7% |
| Asia Pacific [Member] | $513.30M | $521.60M | $563.00M | $639.40M | $688.40M | $546.50M | $505.00M | $495.50M | $461.30M | $427.10M | 19.9% | -1.6% |
| Americas [Member] | $165.40M | $169.30M | $166.50M | $155.40M | $156.60M | $136.60M | $137.30M | $138.30M | $140.00M | $128.30M | 6.4% | -2.3% |
From the segment and revenue-disaggregation notes of Bio-Rad Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.